Prolacta honors and values breastfeeding mothers and their committment to the health of babies
Clinically proven to improve health outcomes of critically ill preemies
Committed to scientific and clinical research in breast milk
Prolact Product Safety


Print the Press Release  Print Version
 

Prolacta Bioscience® to Present at the Cowen and Company 36th Annual Healthcare Conference on March 9, 2016

Scott Elster CEO of Prolacta BioscienceCity of Industry, Calif. Mar 1, 2016 – Prolacta Bioscience ®, the pioneer in human milk-based Neonatal Nutritional Products, announced today that it will present at the 36th Annual Cowen Health Care Conference in Boston, MA. Scott Elster, Prolacta’s President and Chief Executive Officer, is scheduled to present on Wednesday, March 9th, 2016 at 12:00 PM EST.

About Prolacta Bioscience

Prolacta Bioscience, Inc. is a privately-held life sciences company dedicated to Advancing the Science of Human Milk®. The company pioneered the development of human milk-based Neonatal Nutritional Products to meet the needs of critically ill, premature infants in the NICU. Prolacta leads the industry in the quality and safety of nutritional products made from breast milk and operates the first and only pharmaceutical-grade manufacturing facility for the processing of human breast milk. 


Investor Contact:

Candice Knoll
Blueprint Life Science Group
415.375.3340 Ext. 4
cknoll@bplifescience.com


Media Contact:

Loren Kosmont
310.721.9444
Lkosmont@prolacta.com